1. Home
  2. AVLN vs IART Comparison

AVLN vs IART Comparison

Compare AVLN & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$27.52

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

N/A

Current Price

$16.07

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVLN
IART
Founded
2011
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2026
1996

Fundamental Metrics

Financial Performance
Metric
AVLN
IART
Price
$27.52
$16.07
Analyst Decision
Strong Buy
Hold
Analyst Count
4
12
Target Price
★ $62.25
$19.56
AVG Volume (30 Days)
192.8K
★ 725.5K
Earning Date
08-12-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.40
Revenue Next Year
N/A
$3.17
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.90
$8.70
52 Week High
$40.17
$20.49

Technical Indicators

Market Signals
Indicator
AVLN
IART
Relative Strength Index (RSI) 35.91 50.17
Support Level $25.86 $16.04
Resistance Level $30.45 $16.38
Average True Range (ATR) 2.25 0.62
MACD -0.56 0.14
Stochastic Oscillator 14.12 74.87

Price Performance

Historical Comparison
AVLN
IART

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

Share on Social Networks: